AspenBio Pharma aims to sell common shares through public offering

Deal conducted by Aegis, slated to fund general corporate purposes

By Devika Patel

Knoxville, Tenn., Nov. 14 - AspenBio Pharma, Inc. said it plans to conduct a public offering of common stock. Aegis Capital Corp., the bookrunner, has a 45-day greenshoe.

Proceeds will be used for general corporate purposes, including a clinical trial for the company's blood-based appendicitis test and working capital purposes.

AspenBio is a biopharmaceutical company based in Castle Rock, Colo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.